Linaclotide utilization and potential for off-label use and misuse in three European countries

INTRODUCTION: Linaclotide is approved for adults with moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C). Linaclotide is not indicated for weight loss or for patients with inflammatory bowel disease (IBD); it is contraindicated in patients with mechanical bowel obstruction (...

Descripción completa

Detalles Bibliográficos
Autores principales: Cid-Ruzafa, Javier, Lacy, Brian E., Schultze, Anna, Duong, Mai, Lu, Yi, Raluy-Callado, Mireia, Donaldson, Robert, Weissman, Darren, Gómez-Lumbreras, Ainhoa, Ouchi, Dan, Giner-Soriano, Maria, Morros, Rosa, Ukah, Ahunna, Pohl, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189524/
https://www.ncbi.nlm.nih.gov/pubmed/35706826
http://dx.doi.org/10.1177/17562848221100946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189524/
https://www.ncbi.nlm.nih.gov/pubmed/35706826
http://dx.doi.org/10.1177/17562848221100946

Ejemplares similares